Share on StockTwits

United Therapeutics (NASDAQ:UTHR) COO Roger Jeffs sold 10,000 shares of the company’s stock on the open market in a transaction dated Tuesday, May 20th. The stock was sold at an average price of $99.91, for a total transaction of $999,100.00. Following the sale, the chief operating officer now directly owns 1,234 shares in the company, valued at approximately $123,289. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

A number of research firms have recently commented on UTHR. Analysts at Zacks reiterated a “neutral” rating on shares of United Therapeutics in a research note on Thursday, May 1st. They now have a $105.00 price target on the stock. Separately, analysts at Standpoint Research upgraded shares of United Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, April 7th. They now have a $118.00 price target on the stock. Six investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. United Therapeutics has an average rating of “Hold” and an average price target of $96.00.

United Therapeutics (NASDAQ:UTHR) traded up 0.58% on Wednesday, hitting $99.18. The stock had a trading volume of 392,591 shares. United Therapeutics has a one year low of $61.23 and a one year high of $116.65. The stock has a 50-day moving average of $98.5 and a 200-day moving average of $98.93. The company has a market cap of $4.778 billion and a price-to-earnings ratio of 21.42.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Tuesday, April 29th. The company reported $1.77 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.65 by $0.12. The company had revenue of $289.40 million for the quarter, compared to the consensus estimate of $300.14 million. During the same quarter last year, the company posted $1.19 earnings per share. United Therapeutics’s revenue was up 18.1% compared to the same quarter last year. Analysts expect that United Therapeutics will post $7.79 EPS for the current fiscal year.

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.